Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing the long-acting amylin ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Unlock the latest advancements in obesity treatment. Expert insights reveal groundbreaking medical breakthroughs and ...

Amylin has become a hot target for companies aiming to develop the next generation of obesity drugs. Last week, AbbVie joined the field by securing global rights to an engineered peptide Gubra ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

which mimic a hormone called amylin that is co-secreted with insulin. The first wave of obesity drugs was based mainly on the gut hormone GLP-1, but Novo Nordisk is banking on a dual mode of ...

The pharmaceutical industry is not stopping there. There are already 100 new drug candidates in trials, all vying for a slice ...

No. 4 / 2025Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

AbbVie Inc. (NYSE:ABBV) entered the obesity race last week when it in-licensed GUB014295 (also called GUBamy) from Denmark-based Gubra. The candidate is a long-acting amylin analog for the ...

This is a natural step for Roche considering the evolution of the market and amylin representing the next significant drug target to tackle obesity, as a standalone approach and in combination ...